Clinical trials: Systemic Lupus
Lupus Erythematosus, Lupus Nephritis
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis
- Trial name
- EQUALISE (NCT04128579)
- Testing
- Itolizumab [Bmab 600]
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 52 people
- Sponsor
- Biocon Limited
SLE, Lupus Nephritis
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse proliferative and membranous lupus nephritis with severe…
- Conditions
- SLE, Lupus Nephritis, Renal Insufficiency, End-stage Renal Disease
- Trial name
- NCT01207297
- Testing
- Tacrolimus, cyclophosphamide
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Systemic Lupus Erythematosus
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose…
- Trial name
- NCT02885610
- Testing
- RC18 80 mg plus standard therapy, RC18 160 mg plus standard therapy, RC18 240 mg plus standard therapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- RemeGen Co., Ltd.
Systemic Lupus Erythematosus
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07318259
- Testing
- BCMA/CD70 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Lupus Nephritis
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis
This was an open-label, prospective, single-arm, observational study in patients with Lupus nephritis (LN) who newly (i.e.,for the first time) received treatment of Enteric-coated Mycophenolate Sodium (EC-MPS).
- Trial name
- NCT04645589
- Testing
- Myfortic
- Where
- 6 sites in Taiwan
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of CNTO 136 administered intravenously in patients with active, International Society of Nephrology/Renal Pathology Society Class III and IV Lupus Nephritis (LN).
- Trial name
- NCT01273389
- Testing
- CNTO 136
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
System Lupus Erythematosus(SLE)
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.
This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
- Trial name
- NCT07763821
- Volunteers
- 128 people
- Sponsor
- Assiut University
System Lupus Erythematosus(SLE)
Lupus Walking Intervention to Address Fatigue/Quality of Life
Background: Fatigue is a major concern to individuals with lupus, persisting even when disease activity is clinically minimal, and impacting almost all quality of life domains.
- Trial name
- PAL (NCT07481214)
- Testing
- guided increases in daily walking
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- University of California, San Francisco
Systemic Lupus Erythematosus, Lupus Nephritis
Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune system dysregulation and inflammation affecting multiple organs.
- Trial name
- NCT07805863
- Volunteers
- 90 people
- Sponsor
- Assiut University
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
- Trial name
- Tulip SC (NCT04877691)
- Testing
- Medi-546
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Lupus Nephritis
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis
Urinary levels of plasmin ,TF , and TFPI are all elevated in active LN patients compared to inactive LN patients and healthy controls. All four proteins correlated with systemic disease activity and renal disease activity.
- Trial name
- NCT04218890
- Testing
- Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Monoclonal Antibody Treatment for Systemic Lupus Erythematosus
This study will examine the safety and effects of the monoclonal antibody MRA in patients with systemic lupus erythematosus (SLE). Antibodies normally fight invading organisms.
- Trial name
- NCT00046774
- Testing
- MRA 003 US
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Lupus Nephritis
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
This is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants.
- Trial name
- NCT06167174
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
The first part of this study will use the database of a large, ongoing NIH-sponsored lupus study, Safety of Estrogen in Lupus Erythematosus National Assessment.
- Trial name
- SACS-SLE (NCT00000421)
- Testing
- Prednisone
- Where
- 3 sites in United States
- Volunteers
- 154 people
- Sponsor
- NYU Langone Health
Lupus Nephritis
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
The aim of the open multi-center study is to determine an efficient and safe dose and dosing schedule of NKT-01 in induction of response in treatment of lupus nephritis.
- Trial name
- NCT00709722
- Testing
- NKT-01
- Where
- 6 sites in Czechia, Germany
- Volunteers
- 21 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE)
Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
The goal of this study is to learn if mesenchymal stem cell therapy (treatment group) can effectively treat autoimmune diseases, when compared to normal saline (given to placebo group).
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis, Ankylosing Spondylitis (AS)
- Trial name
- MSCs in AD (NCT06888973)
- Testing
- Mesenchymal Stem Cells
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
SLE - Systemic Lupus Erythematosus
Allogeneic UCB-derived CAR-T for SLE
The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults.
- Trial name
- NCT07274059
- Testing
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Chengdu Ucello Biotechnology Co., Ltd.
Nephritis, Lupus
Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis
This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).
- Trial name
- NCT01328834
- Testing
- Tacrolimus Sustained-release Capsules (ADVAGRAF)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.